蛭龙活血通瘀胶囊治疗急性脑梗塞的临床及实验研究
|
摘要
目的:蛭龙活血通瘀胶囊治疗急性脑梗塞有效性及安全性临床研究,并初步探讨其对大鼠缺血再灌注脑梗塞区神经细胞凋亡的影响。方法:1临床部分采用随机、对照、平行试验研究。将符合纳入标准的研究对象按随机数字表1:1随机分入观察组和对照组进行研究。符合病例选择标准共计60例,其中观察组30例,对照组30例。中医诊断、分型标准参照《中药新药治疗中风病的临床研究指导原则》的标准。西医诊断标准参照1995年第4次全国脑血管病学术会议修订的“各类脑血管疾病诊断要点”中有关脑梗死的诊断标准。中医辨证属中风中经络型中的风痰瘀阻型。观察组采用基础治疗加蛭龙活血通瘀胶囊4粒tid,对照组采用基础治疗,2周为一疗程。观察中医证候、中国脑卒中临床神经功能缺损评分(CSS)、美国国立卫生研究院卒中量表(NIHSS)评分、日常生活活动能力量表Barthel指数(BI)评分、实际完成日常生活活动的量表改良Rankin量表(MRS)评分、血脂、血液流变学、血管内皮细胞分泌功能检测及药物安全性监测。2实验部分采用线拴法建立大鼠局灶性脑缺血再灌注损伤模型,将40只雄性SD大鼠随机分为观察组(蛭龙活血通瘀胶囊)10例、对照组(步长脑心通)10例、模型组10例及假手术组10例,用药7天,应用TUNEL法和免疫组织化学法检测各组大鼠脑组织凋亡细胞的分布及bcl-2、Caspase3蛋白的表达。结果:1临床研究(1)治疗后观察组总有效率93.33%,对照组总有效率76.67%,两组有着显著差异(P<0.01);治疗后两组CSS、NIHSS、BI、MRS评分均有不同程度改善,观察组CSS及BI两项评分改善较对照组更为显著(P<0.05);观察组治疗后肢体麻木、口舌歪斜、头晕目眩、痰多而粘、舌象均有明显改善(P<0.01),对照组仅肢体麻木、头晕目眩、脉象三项有所改善(P<0.05),且观察组在改善各症状优于对照组(P<0.05)。(2)治疗后观察组TC、TG和LDL-C显著降低(p<0.01),且疗效显著优于对照组(p<0.05);观察组全血粘度(高切、低切值)、红细胞聚集指数、血沉、血小板聚集率和纤维蛋白原明显下降(p<0.01),疗效显著优于对照组(p<0.01);两组经治疗后血管内皮细胞分泌功能检测指标都有不同程度改善,观察组内皮素(ET)、血栓烷B2(TXB2)、纤溶酶原激活剂抑制物-1(PAI-1)显著降低,并使ET/NO比值显著降低,tPA/PAI比值显著增高(P<0.05,P<0.01),而对照组在ET、6-酮-前列腺素F1a(6-keto-PGF1α)、组织纤溶酶原激活物(tPA)和PAI-1有所改善,但观察组ET,PAI改善较对照组更为明显(P<0.01)。(3)整个观察过程中未发现明显不良事件。2动物实验(1)实验证实了急性脑梗塞缺血再灌注损伤凋亡细胞的存在,模型组脑神经细胞凋亡数量显著高于假手术组(P<0.01),蛭龙活血通瘀组与步长脑心通药物干预组与模型组相比细胞凋亡指数显著下降(P<0.01),但蛭龙活血通瘀组与步长脑心通药物干预组二者比较无明显差异(P>0.05)。(2)免疫组化法检测细胞凋亡基因bcl-2及Caspase3蛋白表达的表达。模型组脑神经细胞bc1-2和Caspase-3基因蛋白表达均显著高于假手术组(P<0.01),与模型组相比,蛭龙活血通瘀组与脑心通组明显上调bc1-2的基因表达(P<0.01),明显抑制Caspase-3基因蛋白表达(P<0.01),蛭龙活血通瘀组与步长脑心通药物干预组间比较无明显差异(P>0.05)。结论:1蛭龙活血通瘀胶囊治疗急性脑梗塞疗效较为满意,能有效改善神经功能缺损评分、中医证候疗效,降低血脂、改善血液流变学指标和改善血管内皮分泌功能失调。2蛭龙活血通瘀胶囊对急性脑梗塞引起的神经细胞凋亡有明显抑制作用。其机制可能与上调bcl-2,抑制Caspase-3有关。
Objective: Zhilong Huoxue Tongyu capsule on the treatment of patients with acute cerebral infarction efficacy and safety of clinical research, and to explore their areas of rat cerebral infarction cell apoptosis.Methods: 1 Part of a Clinical: A randomized, controlled ,Parallel,trial study. Into the standard will be consistent with the object of study by a random number table: a randomized into the treatment group and the control group were studied. Case selection criteria with a total of 60 cases, of which 30 treatment group, the control group of 30 patients. TCM diagnosis, classification criterion-referenced "new Chinese medicine treatment of stroke clinical study of the guiding principles of standards". Western medicine diagnostic criterion-referenced 1995 4th National Conference cerebrovascular disease revised "various cerebrovascular disease diagnosis of cerebral infarction" in the diagnostic criteria. TCM Meridian is a type of stroke in the wind phlegm Yuzu-treatment group based therapy plus a Zhilong Huoxue Tongyu capsule four tid, and the control group used for the basis, for a two week course. Observation security, Syndrome, neurological impairment score, stroke Scale (NIHSS) score, ADL Scale Barthel Index (BI) score, the actual completion of the activities of daily living scale modified Rankin scale (MRS) score, serum lipids, blood rheology, vascular endothelial cell function testing.2 Part of Experimental:Rat model of focal cerebral ischemia, 40 male SD rats were randomly divided into Zhilong Huoxue Tongyu capsule Observer Group 10 cases, step Naoxintong positive control group and 10 cases, the model group 10 and 10 cases of sham-operated group, 7-day drug application TUNEL method and immunohistochemical detection of the rat brain and the distribution of apoptotic bcl-2, Caspase3 immunoreactive cells observation.Results: 1 Clinical results show that: After treatment observation group, the total efficiency of 93.33% in control group, the total efficiency of 76.67%, compared with the significant differences (P<0.01) after treatment groups CSS, NIHSS, BI, in varying degrees MRS score improvement Observer Group CSS and BI score improved significantly more than the control group (P<0.05) observed before and after treatment numbness, and awaking askew, dizziness dizzying, and visco-Tan Zhi, tongue and have significantly improved (P<0.01), the control group only numbness, dizziness dizzying, pulse 3 has improved (P <0.05), and the Observer Group in improving symptoms than the control group (P<0.05); Observer Group to reduce TC, TG, LDL-C, treatment and there is significant difference (P<0.01), and compared with the control group there were significant differences (P<0.05); Observer Group whole blood viscosity (high and low shear value), erythrocyte aggregation index, ESR and platelet aggregation and fibrinogen decreased significantly (P<0.01), and compared with the control group there were significant differences (P<0.01), vascular endothelial cell function testing of the two groups after treatment indicators have improved to varying degrees, Observer Group to endothelin (ET), thromboxane B2 (TXB2), plasminogen activator inhibitor-1 (PAI-1) was significantly reduced, and ET / NO ratio was significantly decreased, and TPA / PAI ratio was significantly higher (P<0.05,P<0.01), while the control group in ET, 6-F1a prostaglandin (6-keto-PGF1α), tissue plasminogen activator (TPA), PAI-1 had improved, but improved compared with the control group more obvious group (P<0.01) in the entire process of observation found no significant adverse events.2 The experimental results show that: Through DNA nick end labeling (TUNEL) confirmed acute cerebral ischemia and reperfusion in the presence of apoptotic cells. Model group neuronal apoptosis was significantly higher than the number of sham-operated group, Huoxue Tongyu group and Naoxintong drug intervention group compared with the model group apoptosis index decreased significantly (P<0.01), indicating Zhilong Huoxue Tongyu capsule and Step long Naoxintong capsule on the brain cells inhibit apoptosis. Immunohistochemistry was used to detect apoptosis gene bcl-2 protein expression and Caspase3 changes. Model group brain cells bc1-2 and Caspase-3 gene expression were significantly higher than the sham-operated group (P<0.01), compared with the model group, Huoxue Tongyu Naoxintong group and the group can enhance bc1-2 gene expression (P< 0.01) significantly inhibited Caspase-3 gene expression (P <0.01).Concusion: 1 Zhilong Huoxue Tongyu capsule treatment of patients with acute cerebral infarction more satisfied with the improvement of neurologic impairment score Syndrome effective than the control group, the main symptom improvement is better than the control group, serum lipid lowering efficacy superior to the control group, improving hemorrheology Indexes, effective than the control group, reversed secretion of vascular endothelial dysfunction, better than the control group. 2 cerebral infarction and neural cell apoptosis, Zhilong Huoxue Tongyu capsule on the treatment of acute cerebral ischemia may be inhibited by injury at the same time block Caspase-3 activation and inhibition of apoptosis alleviate neuronal apoptosis.
Objective: Zhilong Huoxue Tongyu capsule on the treatment of patients with acute cerebral infarction efficacy and safety of clinical research, and to explore their areas of rat cerebral infarction cell apoptosis.Methods: 1 Part of a Clinical: A randomized, controlled ,Parallel,trial study. Into the standard will be consistent with the object of study by a random number table: a randomized into the treatment group and the control group were studied. Case selection criteria with a total of 60 cases, of which 30 treatment group, the control group of 30 patients. TCM diagnosis, classification criterion-referenced "new Chinese medicine treatment of stroke clinical study of the guiding principles of standards". Western medicine diagnostic criterion-referenced 1995 4th National Conference cerebrovascular disease revised "various cerebrovascular disease diagnosis of cerebral infarction" in the diagnostic criteria. TCM Meridian is a type of stroke in the wind phlegm Yuzu-treatment group based therapy plus a Zhilong Huoxue Tongyu capsule four tid, and the control group used for the basis, for a two week course. Observation security, Syndrome, neurological impairment score, stroke Scale (NIHSS) score, ADL Scale Barthel Index (BI) score, the actual completion of the activities of daily living scale modified Rankin scale (MRS) score, serum lipids, blood rheology, vascular endothelial cell function testing.2 Part of Experimental:Rat model of focal cerebral ischemia, 40 male SD rats were randomly divided into Zhilong Huoxue Tongyu capsule Observer Group 10 cases, step Naoxintong positive control group and 10 cases, the model group 10 and 10 cases of sham-operated group, 7-day drug application TUNEL method and immunohistochemical detection of the rat brain and the distribution of apoptotic bcl-2, Caspase3 immunoreactive cells observation.Results: 1 Clinical results show that: After treatment observation group, the total efficiency of 93.33% in control group, the total efficiency of 76.67%, compared with the significant differences (P<0.01) after treatment groups CSS, NIHSS, BI, in varying degrees MRS score improvement Observer Group CSS and BI score improved significantly more than the control group (P<0.05) observed before and after treatment numbness, and awaking askew, dizziness dizzying, and visco-Tan Zhi, tongue and have significantly improved (P<0.01), the control group only numbness, dizziness dizzying, pulse 3 has improved (P <0.05), and the Observer Group in improving symptoms than the control group (P<0.05); Observer Group to reduce TC, TG, LDL-C, treatment and there is significant difference (P<0.01), and compared with the control group there were significant differences (P<0.05); Observer Group whole blood viscosity (high and low shear value), erythrocyte aggregation index, ESR and platelet aggregation and fibrinogen decreased significantly (P<0.01), and compared with the control group there were significant differences (P<0.01), vascular endothelial cell function testing of the two groups after treatment indicators have improved to varying degrees, Observer Group to endothelin (ET), thromboxane B2 (TXB2), plasminogen activator inhibitor-1 (PAI-1) was significantly reduced, and ET / NO ratio was significantly decreased, and TPA / PAI ratio was significantly higher (P<0.05,P<0.01), while the control group in ET, 6-F1a prostaglandin (6-keto-PGF1α), tissue plasminogen activator (TPA), PAI-1 had improved, but improved compared with the control group more obvious group (P<0.01) in the entire process of observation found no significant adverse events.2 The experimental results show that: Through DNA nick end labeling (TUNEL) confirmed acute cerebral ischemia and reperfusion in the presence of apoptotic cells. Model group neuronal apoptosis was significantly higher than the number of sham-operated group, Huoxue Tongyu group and Naoxintong drug intervention group compared with the model group apoptosis index decreased significantly (P<0.01), indicating Zhilong Huoxue Tongyu capsule and Step long Naoxintong capsule on the brain cells inhibit apoptosis. Immunohistochemistry was used to detect apoptosis gene bcl-2 protein expression and Caspase3 changes. Model group brain cells bc1-2 and Caspase-3 gene expression were significantly higher than the sham-operated group (P<0.01), compared with the model group, Huoxue Tongyu Naoxintong group and the group can enhance bc1-2 gene expression (P< 0.01) significantly inhibited Caspase-3 gene expression (P <0.01).Concusion: 1 Zhilong Huoxue Tongyu capsule treatment of patients with acute cerebral infarction more satisfied with the improvement of neurologic impairment score Syndrome effective than the control group, the main symptom improvement is better than the control group, serum lipid lowering efficacy superior to the control group, improving hemorrheology Indexes, effective than the control group, reversed secretion of vascular endothelial dysfunction, better than the control group. 2 cerebral infarction and neural cell apoptosis, Zhilong Huoxue Tongyu capsule on the treatment of acute cerebral ischemia may be inhibited by injury at the same time block Caspase-3 activation and inhibition of apoptosis alleviate neuronal apoptosis.
引文
1.赵建国.脑梗死[M].北京:人民卫生出版社,2006:1
2.郭建文,张晓云,兰万成,等.陈绍宏教授“中风核心病机论”[J].天津中医药,2006,23(1):7～9
3.白雪,王丽萍,王明杰,等.祛风药与活血药对实验性脑缺血大鼠血液流变学的影响[J].中西医结合心脑血管病杂志,2006,4(5):416～417
4.王丽萍,白雪,杨思进,祛风药治疗缺血性中风的研究进展[J].中西医结合心脑血管病杂志2006,4(2):146～148
5.中华医学会神经病学分会.急性缺血性脑卒中患者处理建议(1998)[J].中华神经科杂志,1998,31(5):305～306
6. Li Y,Chopp M,Jiang N,et al.Temporal profile of in situ DNA fragmention after transient middle cereral artery occlusion in the rat[J].Cereb Blood Flow Metab,1995,15(3):389～397
7.刘苏.缺血性中风病因病机的探讨[J].安徽中医临床杂志,2001,13(5):383～384
8. Yamamura T,Otani H,Nakao Y,et al.IGF-1 differentially regulates bcl-xL and Bax and confers myocardial protection in the rat heart[J].Am J Physiol Heart Circ Physiol,2001,280(3):1191～1200
9.彭黎明,王曾礼主编.细胞凋亡的基础与临床[M].北京:人民卫生出版社,2000:112～125
10.白雪.王明杰教授治疗中风的临床经验[J].中国中医急症,2005,14(11):11083～1083
11.余小平.小续命汤加减治疗脑梗塞30例[J].湖南中医杂志,I996,12(6):26
12.郑筱萸.《中药新药临床研究指导原则》(试行)[M].北京:中国医药科技出版社,2002:99～104
13.王维治.《神经病学》[M].北京:人民卫生出版社,2001,130
14.各种脑血管疾病诊断要点[J].中华神经科杂志,1996,29(6):379～380
15. Longa EZ,Weinstin PR,Carlson S,et a1.Reversible middle cerebral artery occlusion without craniectomy in rats [J].Stroke,1989,20(1):84～91
16. Koizumi J,Yoshida Y,Nakazawa T,et a1.Experimental studies of ischemic brain edema.J:A new experimental model of cerebral embolism in rats in which recirculation can be introduced in the ischemia area[J].Stroke,l986,8(1):1～8
17. Bederson JB , Pins LH , Tsuji M , eta1.Rat middle cerebral artery occlusion:evaluation of the model and development of a nurologic examination[J].Stroke,1986,l7(5):472～476
18.叶达平,单守杰,陈绍良,等.不同剂量卡维地络干预对压力超负荷幼鼠心肌细胞凋亡和凋亡相关基因表达的影响[J].中国临床药理学与治疗学.2004,9(7):824～827
19. Treib J,Grauer MT,Woessner R,et a1.Treatment of Stroke on an intensive stroke unit:a novel concept,Intensive care Md[J],2001 Mar;27(3):620-1
20. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group.Tissue plasminogen activator for acute ischemic.Stroke.1995;333:1581～1587
21. Kay R.Wong KS,Yu YL.et a1.Low molecular weight heparin for the treatment of acute ischemic stroke.N Engl J Med 1995;333:1588
22. Li Y,Chopp M,Jiang N,et al. Temporal profile of in situ DNA fragmentation after transient middle cerebral artery occlusion in the rat [J].JCereb Blood Flow Metab,1995,15(3):389～397
23.张学艳,王桂敏,中药对脑缺血损伤时细胞凋亡相关基因调控的作用研究进展[J],医学综述.2007,13(2):145～147
24.高虹,赵菁,缺血性卒中神经细胞凋亡的研究发展[J],中国疗养医学.2007,16(6):383～385
25. Graham SH,Chen J.Programmed cell death in cerebral ischemia.JCereb Blood Flow Metab,2001,21:90～109
26. Finkei E.The mitochondrion:is it central to apoptosis.Science,2001 ,29(270):624～626
27. LilyY,LiZM. Endonuclease G is an apoptotic DNase when released from mitochondria.Nature,2001,412:95～98
28.李样,杨华bcl-2与缺血性脑血管疾病关系的研究进展[J].国外医学老年医学分册,2001,22(2):62～65
29. Nagata S.Apoptosis by death factor[J].Cell,1997,88:355
30. Husng H,Joazeiro CA,Bonfoco E,et al. The inhibitor of apoptosis, cIAP2, functions as a ubiquitin-protein ligase and promotes in vitro monoubiquitination of caspases 3 and 7.JBiol chem.2002,275(35):26661～26614
31.刘宪霜,崔旭,王鲁宁,等.重体腺苷环化酶对缺血再灌注脑神经元凋亡的作用[J].中国临床康复,2003,7(1):34～35
32. Shimamura,Munehisa MD;Sato,Naoyuki MD,PhD;Oshima.KK-azuo MD;et a1.novel therapeutic strategy to treat brain ischemia overexpression of hepatocyte growth factor gene reduced ischemic injury without cerebral edema in rat mode1 [J]Circulation,2004,109(3):424～431
33. Li,Y.MD;Chen,J.MD;Chen,X.MD,PhD:eta1.Human marrow stromal cell therapy for stroke in rat [J].Neurology,2002,59(4):514～523
34. Chen,Jieli MD;Sanberg,Paul R.Phd;Li,YiMD:et a1.Intravenous Administration of human Umbilical Cord Blood Reduces Behavioral Deficits After Stroke in Rats [J].Stroke,2001,32(11):2682～2688
35.陈立峰,等.续命汤颗粒剂治疗中风31例临床观察[J].湖南中医杂志,1997,13(6):5～6
36.冯学功.论肾虚气弱风痰瘀血阻络在缺血性中风恢复期病机中的重要性[J].中医杂志,1998,39(8):156
37.车建国.中风病机与辨治浅论[J].湖南中医杂志,I998,14(5):21～22
38.程金仓,等.芪蛭胶囊治疗缺血性中风恢复期48例[J].山东中医药大学学报,1999,23(3):I98～499
39.冯福海.通络愈瘫胶囊治疗急性缺血性中风的临床研究[J].河南中医,1998,18(2)32
40.谭宝璇,陈朝凤,陈洁文,等.益气活血法抗急性脑梗塞作用机理的实验研究[J].广州中医药大学学报,1999,16(1):41.
41.邓常青,葛金文,胡俊.益气活血药物对氧自由基所致大鼠脑组织损伤的影响[J].湖南中医学院学报,1994,14(2):38
42.王业梅,王键.益气活血法在中风病中的应用研究进展[J].中医药临床杂志,2005,17(1):89～90
43.张斌,雄鹰.黄芪对大鼠急性脑缺血后神经元凋亡的影响[J].中国临床康复,2004,8(31):6968～6969
44.曹翠丽,马常升,马文领,等.中药水蛭对缺血/再灌注后脑细胞的抗凋亡作用[J].河北医科大学学报,2000,21(4):193～195
45.王新高,童萼塘,孙圣刚.补阳还五汤对脑缺血再灌注大鼠皮质神经细胞凋亡的影响[J].现代中西医结合杂志,2005,14(3):306～309.
46.张璇,胡长林.疏血通注射液对大鼠急性脑梗死神经细胞凋亡及相关基因表达的影响[J].江西中医学院学报,2005,17(1):58～60
47.朱兆洪,丁柱,刘彩云.中医药治疗中风病实验研究回顾与思考[J].辽宁中医学院学报,2002,4(4):325～326
48.马培奇.缺血性中风治疗药物现状及其发展趋势[J].中国制药信息,2003,19(8):23～24
49.陈德宇等.中医药治疗缺血性中风近况[J].河南中医2001,21(4):73～75
50.苏振静,谭志霞.中成药治疗脑梗塞的临床应用概述[J],时珍国医国药.2005,16(8).782～782
51.唐灿,尹思源,蒲清荣,等,血脉宁颗粒制备工艺研究[J].泸州医学院学报,2002,25(5):396～399
52.尹思源,杨思进,肖顺汉,等,血脉宁颗粒对瘀血证动物模型有关指标的影响[J].辽宁中医学院学报,2003,5(2):165～166
53.尹思源,肖顺汉,周裔忠,等,瘀血证模型相关指标变化及血脉宁颗粒对其影响的研究[J].河北中医,2003,25(6):478～480
54.陈春富,郭述苏,冯林,等.黄芪对大鼠脑缺血血脑屏障及脑血流的影响[J].卒中与神经疾病,1998,5(3):132～134
55.刘显,刘读文.抗老年性痴呆中药的药理研究概况[J].中医药学报,1998,6:44
56.石瑞如,何路明,等.黄芪对老年大鼠脑M胆碱受体的调节作用[J].中医杂志,1998,14:33
57.陈富春,郭述苏,等.黄芪对大鼠脑缺血血脑屏障及脑血流的影响[J].卒中与神经疾病,1998,5:132
58.曲友直,赵燕玲,秦怀洲,等.黄芪注射液对脑缺血再灌注后的神经细胞凋亡及相关基因表达的影响[J].神经疾病与精神卫生.2007,7(1).13～15
59.南京中医药大学.中药大辞典[M],上海:上海科学技术出版社,2006,第2版:721
60.南京中医药大学.中药大辞典[M],上海:上海科学技术出版社,2006,第2版:725
61.张锡纯.医学衷中参西录[M],河北:河北科学技术出版社,2002,第2版:321
62. Hamon M.Mechanism of thrombosis:physiopathology role of thrombin andits inhibition by modern therapies[J].Arch MAL Coear Vaiss,2006,99(3):5
63.欧兴长,等.水蛭素的研究概况[J].中国药学杂志,1991,26(7):396
64.唐凯.抵当汤等对血液流变性异常大鼠模型的影响[J].浙江中医杂志,1988,(7):319
65.黄震华,许继民.水蛭注射液对大鼠脑缺血再灌注后TNF-α、IL-1β和ICAM-1蛋白表达的影响[J].广西中医学院学报,1995,8(5):306
66.董少龙,闺珊珊,窦维华.水蛭注射液对大鼠脑缺血再灌注损伤神经细胞凋亡的影响[J].广西中医学院学报,2003,8(7):259
67.徐凤彩,高向阳,王炜军,等.蚯蚓体内营养和药物有效成分的研究[J].华南农业大学学报,2001,22(3):86～89
68.殷出梅,储益平,吴鹏.地龙活性提取物的主要药效学实验[J].中草药.2002,33(10):926～928
69.金桂容,徐桂芝.脑梗死的凝血纤溶状态和蚓激酶的作用[J].中国新药与临床杂志.1999,18(1):48
70.徐宗佩,王益明,张吉正,等.地龙提取物对健康小鼠红细胞变形性的影响[J].天津中医,2000,17(3):37
71.李珠莲,梁国建,徐光漪.红藤化学成分研究[J].中草药,1984,15(7):9～11
72.王兆金,王先荣,杨志华.红藤化学成分的研究[J].中草药,1982,13(8):7～9
73.瞿自明.兽医中草药大全[J].北京:中国农业出版社(第一版)l989.624～625
74. Goldstein LB,Bartels C,Davis JN.Interrater reliability of the NIH strokescale[J].Arch Neurol,1989,46:660
75.蒲传强,郎森阳,吴卫平.脑血管病学[M].北京:人民军医出版社,1999年,第一版:530～531
76.张明园,ElenaYu,何燕玲.日常生活能力量表问卷与应用说明[J]上海精神医学,1995,(增刊):5～6
77.徐新春,张慧,张亚敏.中风与血脂水平相关性分析[J],中华临床医学研究杂志,2006,12(1):5～6
78.李艳,李青.丽珠脑力隆胶囊对43例多发腔隙性脑梗塞患者血液流变学及血脂的影响[J],中医研究2006,19(9):49～50
79.莫进达,陆超鹏.灯盏花素注射液对脑梗塞患者智能及血脂的影响[J],右江民族医学院学报,2006,3:386～387
80.谭奇贤.临床血液学和血液检验[M].北京:人民卫生出版社,2004.330
81.王宝忠,杨淑芹.高血压病与健康人毛细血管压及血液流变性检测的对比分析[J].微循环学杂志.1995,5(3):50
82.何国原,刘久波.老年人多发腔隙性脑梗塞的血液流变性[J].微循环学杂志.1995,5(2):5
83.张凡雄,胡坤芳.复方白花前胡液对脑梗塞患者血液流变参数的影响[J],湖北中医杂志,2006,28(9):15～16
84. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature, 1993,362:801～809
85. Yanagisawa M,Kurihara H,Kimura S,et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells.Nature.1988,332:411
86.唐明朝,李代强,张秀英.实验性骨质疏松病理学观察及血清NO和NOS测定的意义[J].右江医学.2005,33(3):220
87.钟平、杨任民、韩永竹,等.大鼠急性脑梗塞血浆及脑组织的NO、ET含量的变化[J].临床神经病学杂志I997,I95
88.王文亮、韩其香、包兴昌.血浆ET,NO,TXB2水平与急性脑梗塞和脑出血的关系及临床意义[J].放射免疫学杂志2002,15(3):144～145
89.吴永红、杨露春.急性脑血管病患者血浆NO和ET含量测定[J].中风与神经疾病杂志1996,14:217
90. Murdoch J.Hall R. Brain protection: physiological and pharmacological considerations. Part I: The physiology of brain injury[J].Can J Anesth.1990,37:663
91.杜金行,止载样,靳洪涛,等.大蒜素对脑局灶缺血大鼠血小板活化功能及其结构的影响[J].中日友好医院学报,2002,11(6),476～477
92.杜文民,王水铭,汤允昭,等.甲基黄酮醇胺对大鼠脑血栓形成模型血小板聚集及血浆TXA2和6-Kete-PGFla水平的影响[J].上海医科大学学报,1999,26(4):271～274
93. AltersA. Hemastatic disturbances in acute ischemic strokes:a study of 86 patients.ActaHaematol,1995,94:10
94.武焕玲,林隆玖,血栓前状态研究进展[J],中国实验诊断学.2003,7(4):277～280
95.石义亭,李德洋,赵毅,等.急性脑梗死患者尿激酶溶栓治疗期间血浆t-PA、PaI-1活性动态变化及临床意义[J].中国临床医学,2000,7(1):66～68
96. Springer JE,Nottingham SA,McEwen ML,et al.Caspase-3 apoptotic signaling following injury to the central nervous system[J].Clin Chem Lab Med,2001,39:299～307
97.王伟,严格控制试验条件,建立标准化脑缺血动物模型[J]中华神经科杂志,1998;31(5):261
1.贺宪武.心脑血管急诊.北京:人民军医出版社,1997:390-404
2.谭奇贤.临床血液学和血液检验[M].北京:人民卫生出版社,2004.33O
3.王宝忠,杨淑芹.高血压病与健康人毛细血管压及血液流变性检测的对比分析.微循环学杂志.1995;5(3):50.
4.何国原,刘久波。老年人多发腔隙性脑梗塞的血渡流变性.微循环学杂志.1995;5(2):5。
5.张凡雄,胡坤芳.复方白花前胡液对脑梗塞患者血液流变参数的影响[J],湖北中医杂志,2006,28(9):15-16
6.孙萍,王璐,赵萍.银杏叶提取物治疗急性脑梗死患者血浆内皮素血栓素、前列环素及血液流变性的研究[J]贵州医药,2006,3O(2):172-173
7.张向宇,高硕等.不同穴位组合对脑梗死患者脑葡萄糖代谢的影响—PET研究[J],中国针灸,2007,27(1):26-30
8.邢成名.缺血性脑血管病[M],北京:人民卫生出版社,2003,197,205
9. Greaves M.Coagulation abnormalities and cerebral infarction[J].J Neurol Neurasurg psychiat,1993,56:433
10.张波,张秋滨,韩荣河等.脑血栓患者急性期血浆t-PA、PAI活性的研究.铁道医学[J],1997,25(1):3
11. Bounameaux H,Godon LA.Plasma measurement of D-dimer as diagnostic aid in suspected venous thrombolism,and overview[J].Thromb Haemost,1994,71:1- 6
12.顾卫,谭峰,吴海科等.清开灵注射液合中风Ⅱ号冲剂治疗脑梗塞及其对t-PA、PAI、GMP-140活性影响的研究[J],中国中医急症,2002,11(5):335-336
13.赵东.乐脉颗粒对老年脑梗塞患者D—二聚体的影响,中国中医药信息杂志[J],2002,1(9);21-22
14.青姚,张志哲等.针刺对脑梗塞患者血浆GMP—140水平变化的研究.医学文选. 2002;21(5): 611-613
15.徐新春,张慧,张亚敏.中风与血脂水平相关性分析,中华临床医学研究杂志[J],2006,12(1):5-6
16.李艳,李青.丽珠脑力隆胶囊对43例多发腔隙性脑梗塞患者血液流变学及血脂的影响[J],中医研究2006,19(9):49-50
17.莫进达,陆超鹏.灯盏花素注射液对脑梗塞患者智能及血脂的影响[J],右江民族医学院学报,2006,3:386-387
18.韩景献,金炫,刘存志等.针刺对脑梗死合并高脂血症患者血脂水平的影响[J],中国针灸,2006,26(6):399-402
19. Allan, S. M., N. J. Rothwell. 2003. Inflammation in central nervous system injury. Phil. Trans. R. Soc. Lond. 358: 1669-1677.
20. del Zoppo, G. J., K. J. Becker, J. M. Hallenbeck. 2001. Inflammation after stroke: is it harmful?. Arch. Neurol. 58: 669-672.
21. Emsley, H. C. A., C. J. Smith, C. M. Gavin, R. F. Georgiou, A. Vail, E. M. Barberan, J. M. Hallenbeck, G. J. del Zoppo, N. J. Rothwell, P. J. Tyrrell, S. J. Hopkins. 2003. An early and sustained peripheral inflammatory response in acute ischaemic stroke: relationships with infection and atherosclerosis. J. Neuroimmunol. 139: 93-101.
22.付庆元,陈桂兰.冬虫夏草对脑梗塞患者免疫功能影响的研究[J],中华临床新医学,2004,4(7):586-587
23.俞征宙,陈荣华,刘楠.中风Ⅱ号方对脑梗塞患者免疫功能的影响[J],2006,16(2):13-15
24.霍则军.电针对大鼠全脑缺血再灌注免疫指标的影响.长春中医学院学报.2000;16(2):46-47
25.张学艳,中药对脑缺血损伤时细胞凋亡相关基因调控的作用研究进展[J],医学综述,2007,13(2):145-147
26.王万铁,陈寿权,王卫等.醒脑静注射液对实验性脑缺血及再灌注损伤中氧自由基水平的影响[J],中医药学刊,2004,22(3):434-435
27.梅爱农,王珏,湛彦强等.通心络胶囊对脑梗死大鼠脑皮质血管新生和皮层神经元凋亡的影响[J],实用医学杂志,2006,22(3):267-270
28.彭海东,涂晋文,田俊.灯盏花素对大鼠脑缺血再灌注后脑含水量和脑组织钙含量的影响[J],湖北中医学院学报,2002,4(3):22-23
2.郭建文,张晓云,兰万成,等.陈绍宏教授“中风核心病机论”[J].天津中医药,2006,23(1):7～9
3.白雪,王丽萍,王明杰,等.祛风药与活血药对实验性脑缺血大鼠血液流变学的影响[J].中西医结合心脑血管病杂志,2006,4(5):416～417
4.王丽萍,白雪,杨思进,祛风药治疗缺血性中风的研究进展[J].中西医结合心脑血管病杂志2006,4(2):146～148
5.中华医学会神经病学分会.急性缺血性脑卒中患者处理建议(1998)[J].中华神经科杂志,1998,31(5):305～306
6. Li Y,Chopp M,Jiang N,et al.Temporal profile of in situ DNA fragmention after transient middle cereral artery occlusion in the rat[J].Cereb Blood Flow Metab,1995,15(3):389～397
7.刘苏.缺血性中风病因病机的探讨[J].安徽中医临床杂志,2001,13(5):383～384
8. Yamamura T,Otani H,Nakao Y,et al.IGF-1 differentially regulates bcl-xL and Bax and confers myocardial protection in the rat heart[J].Am J Physiol Heart Circ Physiol,2001,280(3):1191～1200
9.彭黎明,王曾礼主编.细胞凋亡的基础与临床[M].北京:人民卫生出版社,2000:112～125
10.白雪.王明杰教授治疗中风的临床经验[J].中国中医急症,2005,14(11):11083～1083
11.余小平.小续命汤加减治疗脑梗塞30例[J].湖南中医杂志,I996,12(6):26
12.郑筱萸.《中药新药临床研究指导原则》(试行)[M].北京:中国医药科技出版社,2002:99～104
13.王维治.《神经病学》[M].北京:人民卫生出版社,2001,130
14.各种脑血管疾病诊断要点[J].中华神经科杂志,1996,29(6):379～380
15. Longa EZ,Weinstin PR,Carlson S,et a1.Reversible middle cerebral artery occlusion without craniectomy in rats [J].Stroke,1989,20(1):84～91
16. Koizumi J,Yoshida Y,Nakazawa T,et a1.Experimental studies of ischemic brain edema.J:A new experimental model of cerebral embolism in rats in which recirculation can be introduced in the ischemia area[J].Stroke,l986,8(1):1～8
17. Bederson JB , Pins LH , Tsuji M , eta1.Rat middle cerebral artery occlusion:evaluation of the model and development of a nurologic examination[J].Stroke,1986,l7(5):472～476
18.叶达平,单守杰,陈绍良,等.不同剂量卡维地络干预对压力超负荷幼鼠心肌细胞凋亡和凋亡相关基因表达的影响[J].中国临床药理学与治疗学.2004,9(7):824～827
19. Treib J,Grauer MT,Woessner R,et a1.Treatment of Stroke on an intensive stroke unit:a novel concept,Intensive care Md[J],2001 Mar;27(3):620-1
20. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group.Tissue plasminogen activator for acute ischemic.Stroke.1995;333:1581～1587
21. Kay R.Wong KS,Yu YL.et a1.Low molecular weight heparin for the treatment of acute ischemic stroke.N Engl J Med 1995;333:1588
22. Li Y,Chopp M,Jiang N,et al. Temporal profile of in situ DNA fragmentation after transient middle cerebral artery occlusion in the rat [J].JCereb Blood Flow Metab,1995,15(3):389～397
23.张学艳,王桂敏,中药对脑缺血损伤时细胞凋亡相关基因调控的作用研究进展[J],医学综述.2007,13(2):145～147
24.高虹,赵菁,缺血性卒中神经细胞凋亡的研究发展[J],中国疗养医学.2007,16(6):383～385
25. Graham SH,Chen J.Programmed cell death in cerebral ischemia.JCereb Blood Flow Metab,2001,21:90～109
26. Finkei E.The mitochondrion:is it central to apoptosis.Science,2001 ,29(270):624～626
27. LilyY,LiZM. Endonuclease G is an apoptotic DNase when released from mitochondria.Nature,2001,412:95～98
28.李样,杨华bcl-2与缺血性脑血管疾病关系的研究进展[J].国外医学老年医学分册,2001,22(2):62～65
29. Nagata S.Apoptosis by death factor[J].Cell,1997,88:355
30. Husng H,Joazeiro CA,Bonfoco E,et al. The inhibitor of apoptosis, cIAP2, functions as a ubiquitin-protein ligase and promotes in vitro monoubiquitination of caspases 3 and 7.JBiol chem.2002,275(35):26661～26614
31.刘宪霜,崔旭,王鲁宁,等.重体腺苷环化酶对缺血再灌注脑神经元凋亡的作用[J].中国临床康复,2003,7(1):34～35
32. Shimamura,Munehisa MD;Sato,Naoyuki MD,PhD;Oshima.KK-azuo MD;et a1.novel therapeutic strategy to treat brain ischemia overexpression of hepatocyte growth factor gene reduced ischemic injury without cerebral edema in rat mode1 [J]Circulation,2004,109(3):424～431
33. Li,Y.MD;Chen,J.MD;Chen,X.MD,PhD:eta1.Human marrow stromal cell therapy for stroke in rat [J].Neurology,2002,59(4):514～523
34. Chen,Jieli MD;Sanberg,Paul R.Phd;Li,YiMD:et a1.Intravenous Administration of human Umbilical Cord Blood Reduces Behavioral Deficits After Stroke in Rats [J].Stroke,2001,32(11):2682～2688
35.陈立峰,等.续命汤颗粒剂治疗中风31例临床观察[J].湖南中医杂志,1997,13(6):5～6
36.冯学功.论肾虚气弱风痰瘀血阻络在缺血性中风恢复期病机中的重要性[J].中医杂志,1998,39(8):156
37.车建国.中风病机与辨治浅论[J].湖南中医杂志,I998,14(5):21～22
38.程金仓,等.芪蛭胶囊治疗缺血性中风恢复期48例[J].山东中医药大学学报,1999,23(3):I98～499
39.冯福海.通络愈瘫胶囊治疗急性缺血性中风的临床研究[J].河南中医,1998,18(2)32
40.谭宝璇,陈朝凤,陈洁文,等.益气活血法抗急性脑梗塞作用机理的实验研究[J].广州中医药大学学报,1999,16(1):41.
41.邓常青,葛金文,胡俊.益气活血药物对氧自由基所致大鼠脑组织损伤的影响[J].湖南中医学院学报,1994,14(2):38
42.王业梅,王键.益气活血法在中风病中的应用研究进展[J].中医药临床杂志,2005,17(1):89～90
43.张斌,雄鹰.黄芪对大鼠急性脑缺血后神经元凋亡的影响[J].中国临床康复,2004,8(31):6968～6969
44.曹翠丽,马常升,马文领,等.中药水蛭对缺血/再灌注后脑细胞的抗凋亡作用[J].河北医科大学学报,2000,21(4):193～195
45.王新高,童萼塘,孙圣刚.补阳还五汤对脑缺血再灌注大鼠皮质神经细胞凋亡的影响[J].现代中西医结合杂志,2005,14(3):306～309.
46.张璇,胡长林.疏血通注射液对大鼠急性脑梗死神经细胞凋亡及相关基因表达的影响[J].江西中医学院学报,2005,17(1):58～60
47.朱兆洪,丁柱,刘彩云.中医药治疗中风病实验研究回顾与思考[J].辽宁中医学院学报,2002,4(4):325～326
48.马培奇.缺血性中风治疗药物现状及其发展趋势[J].中国制药信息,2003,19(8):23～24
49.陈德宇等.中医药治疗缺血性中风近况[J].河南中医2001,21(4):73～75
50.苏振静,谭志霞.中成药治疗脑梗塞的临床应用概述[J],时珍国医国药.2005,16(8).782～782
51.唐灿,尹思源,蒲清荣,等,血脉宁颗粒制备工艺研究[J].泸州医学院学报,2002,25(5):396～399
52.尹思源,杨思进,肖顺汉,等,血脉宁颗粒对瘀血证动物模型有关指标的影响[J].辽宁中医学院学报,2003,5(2):165～166
53.尹思源,肖顺汉,周裔忠,等,瘀血证模型相关指标变化及血脉宁颗粒对其影响的研究[J].河北中医,2003,25(6):478～480
54.陈春富,郭述苏,冯林,等.黄芪对大鼠脑缺血血脑屏障及脑血流的影响[J].卒中与神经疾病,1998,5(3):132～134
55.刘显,刘读文.抗老年性痴呆中药的药理研究概况[J].中医药学报,1998,6:44
56.石瑞如,何路明,等.黄芪对老年大鼠脑M胆碱受体的调节作用[J].中医杂志,1998,14:33
57.陈富春,郭述苏,等.黄芪对大鼠脑缺血血脑屏障及脑血流的影响[J].卒中与神经疾病,1998,5:132
58.曲友直,赵燕玲,秦怀洲,等.黄芪注射液对脑缺血再灌注后的神经细胞凋亡及相关基因表达的影响[J].神经疾病与精神卫生.2007,7(1).13～15
59.南京中医药大学.中药大辞典[M],上海:上海科学技术出版社,2006,第2版:721
60.南京中医药大学.中药大辞典[M],上海:上海科学技术出版社,2006,第2版:725
61.张锡纯.医学衷中参西录[M],河北:河北科学技术出版社,2002,第2版:321
62. Hamon M.Mechanism of thrombosis:physiopathology role of thrombin andits inhibition by modern therapies[J].Arch MAL Coear Vaiss,2006,99(3):5
63.欧兴长,等.水蛭素的研究概况[J].中国药学杂志,1991,26(7):396
64.唐凯.抵当汤等对血液流变性异常大鼠模型的影响[J].浙江中医杂志,1988,(7):319
65.黄震华,许继民.水蛭注射液对大鼠脑缺血再灌注后TNF-α、IL-1β和ICAM-1蛋白表达的影响[J].广西中医学院学报,1995,8(5):306
66.董少龙,闺珊珊,窦维华.水蛭注射液对大鼠脑缺血再灌注损伤神经细胞凋亡的影响[J].广西中医学院学报,2003,8(7):259
67.徐凤彩,高向阳,王炜军,等.蚯蚓体内营养和药物有效成分的研究[J].华南农业大学学报,2001,22(3):86～89
68.殷出梅,储益平,吴鹏.地龙活性提取物的主要药效学实验[J].中草药.2002,33(10):926～928
69.金桂容,徐桂芝.脑梗死的凝血纤溶状态和蚓激酶的作用[J].中国新药与临床杂志.1999,18(1):48
70.徐宗佩,王益明,张吉正,等.地龙提取物对健康小鼠红细胞变形性的影响[J].天津中医,2000,17(3):37
71.李珠莲,梁国建,徐光漪.红藤化学成分研究[J].中草药,1984,15(7):9～11
72.王兆金,王先荣,杨志华.红藤化学成分的研究[J].中草药,1982,13(8):7～9
73.瞿自明.兽医中草药大全[J].北京:中国农业出版社(第一版)l989.624～625
74. Goldstein LB,Bartels C,Davis JN.Interrater reliability of the NIH strokescale[J].Arch Neurol,1989,46:660
75.蒲传强,郎森阳,吴卫平.脑血管病学[M].北京:人民军医出版社,1999年,第一版:530～531
76.张明园,ElenaYu,何燕玲.日常生活能力量表问卷与应用说明[J]上海精神医学,1995,(增刊):5～6
77.徐新春,张慧,张亚敏.中风与血脂水平相关性分析[J],中华临床医学研究杂志,2006,12(1):5～6
78.李艳,李青.丽珠脑力隆胶囊对43例多发腔隙性脑梗塞患者血液流变学及血脂的影响[J],中医研究2006,19(9):49～50
79.莫进达,陆超鹏.灯盏花素注射液对脑梗塞患者智能及血脂的影响[J],右江民族医学院学报,2006,3:386～387
80.谭奇贤.临床血液学和血液检验[M].北京:人民卫生出版社,2004.330
81.王宝忠,杨淑芹.高血压病与健康人毛细血管压及血液流变性检测的对比分析[J].微循环学杂志.1995,5(3):50
82.何国原,刘久波.老年人多发腔隙性脑梗塞的血液流变性[J].微循环学杂志.1995,5(2):5
83.张凡雄,胡坤芳.复方白花前胡液对脑梗塞患者血液流变参数的影响[J],湖北中医杂志,2006,28(9):15～16
84. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature, 1993,362:801～809
85. Yanagisawa M,Kurihara H,Kimura S,et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells.Nature.1988,332:411
86.唐明朝,李代强,张秀英.实验性骨质疏松病理学观察及血清NO和NOS测定的意义[J].右江医学.2005,33(3):220
87.钟平、杨任民、韩永竹,等.大鼠急性脑梗塞血浆及脑组织的NO、ET含量的变化[J].临床神经病学杂志I997,I95
88.王文亮、韩其香、包兴昌.血浆ET,NO,TXB2水平与急性脑梗塞和脑出血的关系及临床意义[J].放射免疫学杂志2002,15(3):144～145
89.吴永红、杨露春.急性脑血管病患者血浆NO和ET含量测定[J].中风与神经疾病杂志1996,14:217
90. Murdoch J.Hall R. Brain protection: physiological and pharmacological considerations. Part I: The physiology of brain injury[J].Can J Anesth.1990,37:663
91.杜金行,止载样,靳洪涛,等.大蒜素对脑局灶缺血大鼠血小板活化功能及其结构的影响[J].中日友好医院学报,2002,11(6),476～477
92.杜文民,王水铭,汤允昭,等.甲基黄酮醇胺对大鼠脑血栓形成模型血小板聚集及血浆TXA2和6-Kete-PGFla水平的影响[J].上海医科大学学报,1999,26(4):271～274
93. AltersA. Hemastatic disturbances in acute ischemic strokes:a study of 86 patients.ActaHaematol,1995,94:10
94.武焕玲,林隆玖,血栓前状态研究进展[J],中国实验诊断学.2003,7(4):277～280
95.石义亭,李德洋,赵毅,等.急性脑梗死患者尿激酶溶栓治疗期间血浆t-PA、PaI-1活性动态变化及临床意义[J].中国临床医学,2000,7(1):66～68
96. Springer JE,Nottingham SA,McEwen ML,et al.Caspase-3 apoptotic signaling following injury to the central nervous system[J].Clin Chem Lab Med,2001,39:299～307
97.王伟,严格控制试验条件,建立标准化脑缺血动物模型[J]中华神经科杂志,1998;31(5):261
1.贺宪武.心脑血管急诊.北京:人民军医出版社,1997:390-404
2.谭奇贤.临床血液学和血液检验[M].北京:人民卫生出版社,2004.33O
3.王宝忠,杨淑芹.高血压病与健康人毛细血管压及血液流变性检测的对比分析.微循环学杂志.1995;5(3):50.
4.何国原,刘久波。老年人多发腔隙性脑梗塞的血渡流变性.微循环学杂志.1995;5(2):5。
5.张凡雄,胡坤芳.复方白花前胡液对脑梗塞患者血液流变参数的影响[J],湖北中医杂志,2006,28(9):15-16
6.孙萍,王璐,赵萍.银杏叶提取物治疗急性脑梗死患者血浆内皮素血栓素、前列环素及血液流变性的研究[J]贵州医药,2006,3O(2):172-173
7.张向宇,高硕等.不同穴位组合对脑梗死患者脑葡萄糖代谢的影响—PET研究[J],中国针灸,2007,27(1):26-30
8.邢成名.缺血性脑血管病[M],北京:人民卫生出版社,2003,197,205
9. Greaves M.Coagulation abnormalities and cerebral infarction[J].J Neurol Neurasurg psychiat,1993,56:433
10.张波,张秋滨,韩荣河等.脑血栓患者急性期血浆t-PA、PAI活性的研究.铁道医学[J],1997,25(1):3
11. Bounameaux H,Godon LA.Plasma measurement of D-dimer as diagnostic aid in suspected venous thrombolism,and overview[J].Thromb Haemost,1994,71:1- 6
12.顾卫,谭峰,吴海科等.清开灵注射液合中风Ⅱ号冲剂治疗脑梗塞及其对t-PA、PAI、GMP-140活性影响的研究[J],中国中医急症,2002,11(5):335-336
13.赵东.乐脉颗粒对老年脑梗塞患者D—二聚体的影响,中国中医药信息杂志[J],2002,1(9);21-22
14.青姚,张志哲等.针刺对脑梗塞患者血浆GMP—140水平变化的研究.医学文选. 2002;21(5): 611-613
15.徐新春,张慧,张亚敏.中风与血脂水平相关性分析,中华临床医学研究杂志[J],2006,12(1):5-6
16.李艳,李青.丽珠脑力隆胶囊对43例多发腔隙性脑梗塞患者血液流变学及血脂的影响[J],中医研究2006,19(9):49-50
17.莫进达,陆超鹏.灯盏花素注射液对脑梗塞患者智能及血脂的影响[J],右江民族医学院学报,2006,3:386-387
18.韩景献,金炫,刘存志等.针刺对脑梗死合并高脂血症患者血脂水平的影响[J],中国针灸,2006,26(6):399-402
19. Allan, S. M., N. J. Rothwell. 2003. Inflammation in central nervous system injury. Phil. Trans. R. Soc. Lond. 358: 1669-1677.
20. del Zoppo, G. J., K. J. Becker, J. M. Hallenbeck. 2001. Inflammation after stroke: is it harmful?. Arch. Neurol. 58: 669-672.
21. Emsley, H. C. A., C. J. Smith, C. M. Gavin, R. F. Georgiou, A. Vail, E. M. Barberan, J. M. Hallenbeck, G. J. del Zoppo, N. J. Rothwell, P. J. Tyrrell, S. J. Hopkins. 2003. An early and sustained peripheral inflammatory response in acute ischaemic stroke: relationships with infection and atherosclerosis. J. Neuroimmunol. 139: 93-101.
22.付庆元,陈桂兰.冬虫夏草对脑梗塞患者免疫功能影响的研究[J],中华临床新医学,2004,4(7):586-587
23.俞征宙,陈荣华,刘楠.中风Ⅱ号方对脑梗塞患者免疫功能的影响[J],2006,16(2):13-15
24.霍则军.电针对大鼠全脑缺血再灌注免疫指标的影响.长春中医学院学报.2000;16(2):46-47
25.张学艳,中药对脑缺血损伤时细胞凋亡相关基因调控的作用研究进展[J],医学综述,2007,13(2):145-147
26.王万铁,陈寿权,王卫等.醒脑静注射液对实验性脑缺血及再灌注损伤中氧自由基水平的影响[J],中医药学刊,2004,22(3):434-435
27.梅爱农,王珏,湛彦强等.通心络胶囊对脑梗死大鼠脑皮质血管新生和皮层神经元凋亡的影响[J],实用医学杂志,2006,22(3):267-270
28.彭海东,涂晋文,田俊.灯盏花素对大鼠脑缺血再灌注后脑含水量和脑组织钙含量的影响[J],湖北中医学院学报,2002,4(3):22-23